Clinical trial
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00301964 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00301964 |
|---|---|
| Title | Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| Official title | A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC# 704865, IND # 7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Endometrial Carcinoma |
| Intervention type | Biological, Other |
| Interventions | bevacizumab, laboratory biomarker analysis |
| Enrollment | 56 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Mar 13, 2006 |
| Last update posted | Jul 24, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: